Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Breast cancer, early stage

4821 - Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies


20 Oct 2018


Poster Discussion session - Breast cancer, early stage


Cytotoxic Therapy;  Targeted Therapy

Tumour Site

Breast Cancer


Giampaolo Bianchini


Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270


G. Bianchini1, J. Parker2, L. Carey3, C.M. Perou2, L. Sica1, A. Prat4, T. Pieńkowski5, Y. Im6, G.V. Bianchi7, T. Ling-Ming8, M. Liu9, A. Lluch10, V. Semiglazov11, J. de la Haba-Rodriguez12, D. Oh13, B. Poirier14, J.L. Pedrini15, P. Valagussa16, L. Gianni1

Author affiliations

  • 1 Medical Oncology, IRCCS San Raffaele, 20132 - Milan/IT
  • 2 Cancer Genetics, University of North Carolina - Chapel Hill, Chapel Hill/US
  • 3 Hematology/oncology, University of North Carolina - Chapel Hill, 27599 - Chapel Hill/US
  • 4 Medical Oncology  , Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 5 Onkologia Kliniczna, Radomskie Centrum Onkologii, 26-600 - Radom/PL
  • 6 Sungkyunkwan University School Of Medicine, Samsung Medical Center, Seoul/KR
  • 7 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 8 Department Of Surgery, Taipei Veterans Hospital, Taipei/TW
  • 9 Medical Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei/TW
  • 10 Medical Oncology, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 11 Medical Oncology, 14NN Petrov Research Institute of Oncology, St Petersburg/RU
  • 12 Medical Oncology, Hospital Reina Sofia, Cordoba/ES
  • 13 Medical Oncology, Seoul National University Hospital, 110-744 - Seoul/KR
  • 14 Medical Oncology, Centre des maladies du sein, Hôpital du Saint-Sacrement, Québec/CA
  • 15 Department Of Surgery, Hospital Ernesto Dornelles, Porto Alegre/BR
  • 16 Operative Office, Fondazione Michelangelo, Milan/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4821


In the NeoSphere trial, we assessed research-based PAM50 subtype predictors at baseline in all patients (pts), and at surgery (SX) in pts with residual disease (RD) to investigate the changes after treatment and the association with pCR and distant event free survival (DEFS).


417 HER2+ pts were randomized to neoadjuvant TD, TPD, TP or PD (T=trastuzumab, P=pertuzumab, D=docetaxel), and received FAC/FEC and T after SX. 296 pts had RD. We assessed the intrinsic subtypes, ROR-P and ROR-S in 350 (83.9%) and 191 (64.5%) pts at baseline and SX respectively (166 paired samples). We evaluated the association with pCR and DEFS in the overall population and by ER status (161 (46.0%) ER+; 189 (54%) ER-).


The intrinsic subtype distribution was different by ER status. After adjustment for ER, no significant association with pCR was found. None of the baseline biomarkers was associated with DEFS in the overall population. In ER+, Her2-enriched (Her2E) subtype was associated with worst prognosis (HR 3.00 [1.10-8.22]; p = 0.032). Higher ROR-P and ROR-S were significantly associated with higher risk of recurrence in ER+ only (test for interaction p = 0.035 and p = 0.012, respectively). At SX, there was a significant increase in LumA and a decrease in Her2E and LumB subtypes. ROR scores also decreased. In ER+, post-treatment Her2E (HR 7.50 [1.86-30.1]; p = 0.044) and LumB (HR 3.12 [1.03-9.94]; p = 0.004) subtypes were associated with worst outcome than LumA. ROR-S and ROR-P were associated with outcome in ER+ tumors only (significant test for interaction). Compared to low-ROR-S group, high (HR 10.5 [2.79-39.3]; p = 0.0005) and median (HR 3.52 [1.11-11.4]; p = 0.032) groups had higher recurrence risk. Five year-DEFS was 94%, 78% and 50% in the low, median and high ROR-S groups, respectively. In paired samples, the post-treatment biomarker assessment was more informative than at baseline.


In the NeoSphere study, PAM50 provides different prognostic information in ER+ and ER- tumors. Pre-treatment biomarkers were less informative than post-treatment, reflecting their dynamic modulation. In ER+ tumors with RD, PAM50-derived scores assessed on surgical samples might identify patients who need treatment escalation. This warrants independent validation.

Clinical trial identification

Legal entity responsible for the study

Fondazione Michelangelo.


Has not received any funding.

Editorial Acknowledgement


G. Bianchini: Consultant or advisory board member: Roche, EISAI, Pfizer, AstraZeneca, Novartis, MSD, Lilly, Amgen. C.M. Perou: Equity stock holder, consultant, and Board of Director Member: BioClassifier LLC; Listed an inventor on patent applications on the Breast PAM50 assay. A. Prat: Consultancy: Pfizer, Eli Lilly, Novartis, Nanostring Technologies Research funding Novartis, Nanostring Technologies; Scientific advisory board: Oncolytics Biotech. L. Gianni: Consultant or advisor board member: Roche, Pfizer, Boehringer Ingelheim, Celgene, Tahio Pharmaceutical, Synthon, AstraZeneca, Genomic Health, Merck Sharp & Dohme, Synaffix, Eli Lilly, Odonate Therapeutics, Sandoz, Onkaido, Oncolytics Biotech, ADC Therapeutics, Seattle Genetics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.